Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom

Emerging infectious diseases 2026 Open access

Read full text
Authors: Victoria Sheridan, Craig W. Duffy, Jake Dunning, Lance Turtle, Julian A. Hiscox, Krishanthi S. Subramaniam, on behalf of the ISARIC4C Investigators
DOI: 10.3201/eid3202.251553
Cited by: 2
References: 9

Abstract

A 2-dose regimen of the vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN) can generate neutralizing antibodies for monkeypox virus clades Ib and IIb. We observed higher response to clade IIb; that result provides evidence that MVA-BN vaccination can induce cross-neutralizing antibodies for monkeypox virus clade Ib as well as for clade IIb.

Fields of Study & Subjects

Poxvirus research and outbreaks Lymphadenopathy Diagnosis and Analysis vaccines and immunoinformatics approaches

Publication details

Journal / source
Emerging infectious diseases
Publisher
Centers for Disease Control and Prevention (CDC)
Volume
32
Issue
2
Pages
302–305
Publication date
1 February 2026
Language
EN